首页 | 本学科首页   官方微博 | 高级检索  
     

依达拉奉联合他汀类药物对缺血性脑卒中患者血清同型半胱氨酸、C反应蛋白、血脂水平的影响
引用本文:陆云南,华烨,冯志强,马涛,何培成,吴双双,许红. 依达拉奉联合他汀类药物对缺血性脑卒中患者血清同型半胱氨酸、C反应蛋白、血脂水平的影响[J]. 实用临床医药杂志, 2017, 21(19). DOI: 10.7619/jcmp.201719008
作者姓名:陆云南  华烨  冯志强  马涛  何培成  吴双双  许红
作者单位:1. 南京医科大学附属无锡市第二人民医院神经内科,江苏无锡,214000;2. 江苏省人民医院,江苏南京,210000
基金项目:2015年江苏省干部保健科研课题
摘    要:目的观察缺血性脑卒中患者在给予依达拉奉联合他汀类药物治疗后血清同型半胱氨酸(Hcy)、C反应蛋白(CRP)、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL)和低密度脂蛋白胆固醇(LDL-C)水平变化。方法 63例脑卒中患者分为2组,对照组27例给予瑞舒伐他汀,观察组36例在对照组治疗基础上给予依达拉奉治疗。检测体内Hcy、TG、TC、HDL及LDL-C水平变化,同时在治疗前与治疗14 d后填写脑卒中量表NIHSS、日常生活能力Barthel指数自评表、焦虑自评表(SAS)及抑郁自评表(SDS)。结果观察组Hcy、CRP及LDL-C水平显著低于对照组,HDL显著高于对照组。观察组患者在治疗14 d后总有效率达88.89%,显著高于对照组的77.78%。观察组患者Barthel指数显著高于对照组,SAS、SDS指数均显著低于对照组(P0.05)。结论依达拉奉联合瑞舒伐他汀可显著提高缺血性脑卒中患者的治疗效果,优化患者预后及生活能力。

关 键 词:缺血性脑卒中  依达拉奉  同型半胱氨酸  C反应蛋白  预后

Effect of edaravone combined with statins on serum homocysteine,C-reactive protein and lipid levels in patients with ischemic stroke
LU Yunnan,HUA Ye,FENG Zhiqiang,MA Tao,HE Peicheng,WU Shuangshuang,XU Hong. Effect of edaravone combined with statins on serum homocysteine,C-reactive protein and lipid levels in patients with ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2017, 21(19). DOI: 10.7619/jcmp.201719008
Authors:LU Yunnan  HUA Ye  FENG Zhiqiang  MA Tao  HE Peicheng  WU Shuangshuang  XU Hong
Abstract:Objective To analyze the effect of edaravone combined with statins on levels of serum homocysteine (Hcy),C-reactive protein (CRP) and total cholesterol (TC),triglyceride (TG),high-density lipoprotein HDL),low-density lipoprotein cholesterol (LDL-C) in patients with ischemic stroke.Methods A total of 63 patients with ischemic stroke in our hospital were divided into two groups,27 cases in control group were given atorvastatin,and 36 patients in the observation group were given edaravone treatment in addition.The levels of Hcy,TG,TC,HDL and low LDL-C were detected.At the same time,stroke scale of NIHSS,Barthel index of daily living ability,Self Anxiety Scale (SAS) and Self Depression Scale (SDS) were recorded at 14 days before and after treatment.Results The observation group had lower Hcy,CRP and LDL-C levels,while higher HDL level.Total effective rate in the observation group was significantly higher than the control group (88.89% vs.77.78%,P <0.05).The observation group had higher Barthel index and lower SAS,SDS scores than the control group (P < 0.05).Conclusion Edaravone combined with atorvastatin can significantly improve patients' treatment outcomes,and improve prognosis and life ability.
Keywords:ischemic stroke  edaravone  homocysteine  C-reactive protein  prognosis
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号